ArticleJournal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer2015
Refining Prognosis in Lung Cancer: A Report on the Quality and Relevance of Clinical Prognostic Tools.
Article in Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Critical appraisal of predictive tools to assess the difficulty of laparoscopic liver resection: a systematic review.Surgical endoscopy · 2019Pooled it
- Personalizing prognosis in colorectal cancer: A systematic review of the quality and nature of clinical prognostic tools for survival outcomes.Journal of surgical oncology · 2017Pooled it
- Decision support systems for incurable non-small cell lung cancer: a systematic review.BMC medical informatics and decision making · 2017Pooled it
- Development and Validation of EsoTIME, a Prognostication Tool for Resected Esophageal and Gastroesophageal Cancer.Annals of surgical oncology · 2026Article
- Defining the surgical curative time window: identifying patients with an absence of recurrence for 5 years following surgical resection of stage I invasive non-small cell lung cancer.Translational lung cancer research · 2025Article
- Article
- External validation of a novel cancer-associated venous thromboembolism risk assessment score in a safety-net hospital.Research and practice in thrombosis and haemostasis · 2025Article
- Association between renal dysfunction and outcomes of lung cancer: A systematic review and meta‑analysis.Oncology letters · 2024Article
- Article
- Disease prognosis and therapeutic strategies in patients with advanced non-small cell lung cancer (NSCLC): a 6-year epidemiological study between 2015-2021.Translational cancer research · 2024Article
- Predicting 2-year survival in stage I-III non-small cell lung cancer: the development and validation of a scoring system from an Australian cohort.Radiation oncology (London, England) · 2022Article
- Machine Learning for Prediction of Survival Outcomes with Immune-Checkpoint Inhibitors in Urothelial Cancer.Cancers · 2021Article
- Biomarker Discovery and Validation: Statistical Considerations.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2021Article
- Prognostic Factors Determining Survival of Patients Operated for Non-Small Cell Lung Cancer with Consideration Given to Morphological Parameters of Blood.Cancer management and research · 2021Article
- Article
- Survival score to characterize prognosis in inoperable stage III NSCLC after chemoradiotherapy.Translational lung cancer research · 2019Article
- Development and Validation of a Nomogram Prognostic Model for Patients With Advanced Non-Small-Cell Lung Cancer.Cancer informatics · 2019Article
- The developing role of FDG PET imaging for prognostication and radiotherapy target volume delineation in non-small cell lung cancer.Journal of thoracic disease · 2018Review
- An overview of mortality & predictors of small-cell and non-small cell lung cancer among Saudi patients.Journal of epidemiology and global health · 2018Review
- The Limitations of Standard Clinicopathologic Features to Accurately Risk-Stratify Prognosis after Resection of Intrahepatic Cholangiocarcinoma.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
introductionAccurate, individualized prognostication for lung cancer patients requires the integration of standard patient and pathologic factors, biological, genetic, and other molecular characteristics of the tumor. Clinical prognostic tools aim to aggregate information on an individual patient to predict disease outcomes such as overall survival, but little is known about their clinical utility and accuracy in lung cancer.
methodsA systematic search of the scientific literature for clinical prognostic tools in lung cancer published from January 1, 1996 to January 27, 2015 was performed. In addition, web-based resources were searched. A priori criteria determined by the Molecular Modellers Working Group of the American Joint Committee on Cancer were used to investigate the quality and usefulness of tools. Criteria included clinical presentation, model development approaches, validation strategies, and performance metrics.
resultsThirty-two prognostic tools were identified. Patients with metastases were the most frequently considered population in non-small-cell lung cancer. All tools for small-cell lung cancer covered that entire patient population. Included prognostic factors varied considerably across tools. Internal validity was not formally evaluated for most tools and only 11 were evaluated for external validity. Two key considerations were highlighted for tool development: identification of an explicit purpose related to a relevant clinical population and clear decision points and prioritized inclusion of established prognostic factors over emerging factors.
conclusionsPrognostic tools will contribute more meaningfully to the practice of personalized medicine if better study design and analysis approaches are used in their development and validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.